Summit and the US ECOG-ACRIN research group announced a registration-enabling phase 2/3 study of Akeso-originated ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The notable signal is a prospective test of whether a…
AstraZeneca agreed to invest $2.0 billion in newly issued Summit Therapeutics convertible preferred equity and to test Summit’s ivonescimab with AstraZeneca antibody-drug conjugates. The initial collaboration pairs ivonescimab, a PD-1/VEGF bispecific originally engineered by…
Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind Phase III study in 398 patients with PD-L1-positive advanced non-small-cell lung cancer in China. The…
